




EffeMarket

## CAR-T Pipeline Report in Oncology-2018

**December 2018**



## Table of Content

- Executive Summary
- Key Question Answered
- CAR-T Introduction
  - Monoclonal antibodies (MABs)
  - Checkpoint Inhibitors
  - Cytokines
  - Vaccines
  - Adoptive Cell transfer (ACT)
  - CAR-T Cell Therapy
    - Structure of CAR-T Cells
  - Work Process of CAR-T Cell therapy
  - Progression in CAR-T cells research
    - First Generation CAR-T cells
    - Second Generation CAR-T cells
    - Third generation
    - Fourth generation
  - Types of CAR-T Cells
    - TRUCK CAR
    - Universal CAR
    - Self-driving CAR
    - Armored CAR
    - Self-destruct CAR
    - Conditional CAR
    - Marked CAR
    - TanCAR
    - Dual CAR
    - sCAR
  - Approved CAR-T cell therapy
    - Yescarta (axicabtagene ciloleucel, KTE-C19, KTE-X19)
      - Pivotal Study of Yescarta
      - Phase III Study of Yescarta
      - Phase II Study of Yescarta
      - Phase I/II Study of Yescarta
      - Phase I/II Combination Study of axicabtagene ciloleucel with Atezolizumab
      - Phase I/II Combination Study of axicabtagene ciloleucel with Utomilumab
      - Expanded Access Study of Yescarta
    - Kymriah (tisagenlecleucel)
      - Pivotal Study of Kymriah for Acute lymphoblastic leukemia (ALL)
      - Pivotal Study of Kymriah for Diffuse Large B-Cell Lymphoma (DLBCL)

- Phase III study of Kymriah
- Phase I Combination study of Kymriah
- Targets of CAR-T cell therapy
  - Target Introduction
- Pipeline of CAR-T cell therapy
  - Pipeline Analysis by Phase of Molecule
    - Phase I Molecules
    - Phase II Molecules
    - Phase III Molecules
      - bb2121 (BCMA CAR-T)
        - Collaboration
          - Phase I study of bb2121
          - Phase II studies of bb2121
          - Phase III study of bb2121
        - lisocabtagene maraleucel (JCAR017; liso-cel)
          - Phase III study of lisocabtagene maraleucel
          - Phase II study of lisocabtagene maraleucel
          - Phase I Study of lisocabtagene maraleucel
- Preclinical Molecules
- Discovery Phase Molecules
- Unknown Phase Molecules
- Pipeline Analysis by Indication
- Major Collaboration/Partnership for CAR-T cells developments
  - Acquisitions
- About EffeMarket
- Disclaimer
- Contact US

## List of Figures

Figure 1: Structure of CAR-T cells

Figure 2: Work Process of CAR-T Cell therapy

Figure 3: Progression in CAR-T cells therapy research

Figure 4: Number of Molecules in Different Phase of development

Figure 5: Pipeline Analysis by Indication

Figure 6: Pipeline Analysis by Phase III

Figure 7: Pipeline Analysis by Phase II

Figure 8: Pipeline Analysis by Phase I

Figure 9: Pipeline Analysis by Preclinical Phase

Figure 10: Pipeline Analysis by Phase Unknown

Figure 11: Pipeline Analysis by Discovery Phase

## List of Tables

Table 1: CAR-T Therapy Targets
Table 2: Phase I Molecules (1/45)
Table 3: Phase I Molecules (2/45)
Table 4: Phase I Molecules (3/45)
Table 5: Phase I Molecules (4/45)
Table 6: Phase I Molecules (5/45)
Table 7: Phase I Molecules (6/45)
Table 8: Phase I Molecules (7/45)
Table 9: Phase I Molecules (8/45)
Table 10: Phase I Molecules (9/45)
Table 11: Phase I Molecules (10/45)
Table 12: Phase I Molecules (11/45)
Table 13: Phase I Molecules (12/45)
Table 14: Phase I Molecules (13/45)
Table 15: Phase I Molecules (14/45)
Table 16: Phase I Molecules (15/45)
Table 17: Phase I Molecules (16/45)
Table 18: Phase I Molecules (17/45)
Table 19: Phase I Molecules (18/45)
Table 20: Phase I Molecules (19/45)
Table 21: Phase I Molecules (20/45)
Table 22: Phase I Molecules (21/45)
Table 23: Phase I Molecules (22/45)
Table 24: Phase I Molecules (23/45)
Table 25: Phase I Molecules (24/45)
Table 26: Phase I Molecules (25/45)
Table 27: Phase I Molecules (26/45)
Table 28: Phase I Molecules (27/45)
Table 29: Phase I Molecules (28/45)
Table 30: Phase I Molecules (29/45)
Table 31: Phase I Molecules (30/45)
Table 32: Phase I Molecules (31/45)
Table 33: Phase I Molecules (32/45)
Table 34: Phase I Molecules (33/45)
Table 35: Phase I Molecules (34/45)
Table 36: Phase I Molecules (35/45)
Table 37: Phase I Molecules (36/45)
Table 38: Phase I Molecules (37/45)
Table 39: Phase I Molecules (38/45)
Table 40: Phase I Molecules (39/45)

Table 41: Phase I Molecules (40/45)  
Table 42: Phase I Molecules (41/45)  
Table 43: Phase I Molecules (42/45)  
Table 44: Phase I Molecules (43/45)  
Table 45: Phase I Molecules (44/45)  
Table 46: Phase I Molecules (45/45)  
Table 47: Phase II Molecules (1/2)  
Table 48: Phase II Molecules (2/2)  
Table 49: Phase III Molecules  
Table 50: Preclinical Molecules (1/30)  
Table 51: Preclinical Molecules (2/30)  
Table 52: Preclinical Molecules (3/30)  
Table 53: Preclinical Molecules (4/30)  
Table 54: Preclinical Molecules (5/30)  
Table 55: Preclinical Molecules (6/30)  
Table 56: Preclinical Molecules (7/30)  
Table 57: Preclinical Molecules (8/30)  
Table 58: Preclinical Molecules (9/30)  
Table 59: Preclinical Molecules (10/30)  
Table 60: Preclinical Molecules (11/30)  
Table 61: Preclinical Molecules (12/30)  
Table 62: Preclinical Molecules (13/30)  
Table 63: Preclinical Molecules (14/30)  
Table 64: Preclinical Molecules (15/30)  
Table 65: Preclinical Molecules (16/30)  
Table 66: Preclinical Molecules (17/30)  
Table 67: Preclinical Molecules (18/30)  
Table 68: Preclinical Molecules (19/30)  
Table 69: Preclinical Molecules (20/30)  
Table 70: Preclinical Molecules (21/30)  
Table 71: Preclinical Molecules (22/30)  
Table 72: Preclinical Molecules (23/30)  
Table 73: Preclinical Molecules (24/30)  
Table 74: Preclinical Molecules (25/30)  
Table 75: Preclinical Molecules (26/30)  
Table 76: Preclinical Molecules (27/30)  
Table 77: Preclinical Molecules (28/30)  
Table 78: Preclinical Molecules (29/30)  
Table 79: Preclinical Molecules (30/30)  
Table 80: Discovery Phase Molecules (1/6)  
Table 81: Discovery Phase Molecules (2/6)  
Table 82: Discovery Phase Molecules (3/6)

Table 83: Discovery Phase Molecules (4/6)

Table 84: Discovery Phase Molecules (5/6)

Table 85: Discovery Phase Molecules (6/6)

Table 86: Unknown Phase Molecules (1/2)

Table 87: Unknown Phase Molecules (2/2)

## About EffeMarket

EffeMarket provides market and business research solutions to clients in over 20 industries through syndicated studies, custom research, consulting engagements and newsletters. Our experienced analyst and widespread network of experts ensures accuracy within studies and provides our patrons with extensively researched, fact-based insights that help you to take better decisions.

## Disclaimer

EffeMarket reports and their contents, including all the analysis and research containing valuable market information, are provided to a select group of customers in response to orders. Our customers acknowledge when ordering that EffeMarket reports including all research and insights in their entirety are for our customers' internal use and not for general publication or disclosure to third parties. The market information is based primarily on secondary research and interviews and therefore, is subject to changes. EffeMarket takes no responsibility for any incorrect information supplied to us through such sources.

## Contact US

For any questions and updates, please contact:

[Sales@effemarket.com](mailto:Sales@effemarket.com)

[Support@effemarket.com](mailto:Support@effemarket.com)

Website: [www.effemarket.com](http://www.effemarket.com)

**Phone:**

US: +1-972-256-8133

UK: +44-207-993-8632

IN: +91 120 4561797

**Address:** Effectual Knowledge Services Pvt. Ltd. B-55, Sector 2, Noida – 201301, U.P., India  
US Office – New York  
Effectual Knowledge Services, Inc. 425 Broadhollow Road, Suite 427, Melville | NY 11747